The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Prof Ray is currently President of the European Atherosclerosis Society, Chair of the World Heart Federation Cholesterol Roadmap 2021 2022, Chair for Global Council for Heart Health. National Lead for CVD N I HR Academic research Collaboration, Clinical Director for Research HDR UK Digital Innovation Hub DISCOVER Now. He received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge. His research involves lipids, diabetes and population health serving as global lead for trials and registries. He has >100 000 citations and since 2018 has been recognised annually by Clarivate Analytics as among the top 0.1% of authors in global medicine.
He lead the international development program for Inclisiran, the first siRNA based therapy for cholesterol lowering approved globally , in addition to playing a key role in the development program of Bempedoic A cid and PCSK9 monoclonal antibodies. He initiated the Familial Hypercholesterolaemia Studies Collaboration (FHSC), the only global registry of FH, as well as multinational European registries such as Da Vinci, Heymans and Santorini , all of which are helping to shape global health policy.